Canaccord Downgrades ResMed (RMD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $240.51 --0%
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 32 | New: 6
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 32 | New: 6
Join SI Premium – FREE
Canaccord analyst Shane Storey downgraded ResMed (NYSE: RMD) from Buy to Hold.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $229.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Downgrades MNTN Inc (MNTN) to In Line
- Lexicon Pharma (LXRX) Tops Q3 EPS by 3c
- Evolent Health (EVH) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
